CClinicalTrials.gg
CompletedNCT03170427Updated Oct 23, 2017

Impedance Cardiography as Tool for Continuous Hemodynamic Monitoring During Cesarean Section

An interventional study of Impedance cardiography and Sensory levels in Cesarean Section Complications, sponsored by University of Foggia. Completed. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-10-23.

Sponsored by University of Foggia · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 4 years 4 months after the study started (first participant enrolled Jan 2013, registered May 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Impedance Cardiography (ICG) is a non-invasive tool for continuous hemodynamic monitoring. Aims of our study is to assess the utility of ICG to evaluate the hemodynamic impact of 6 mg (GL6) vs 8 mg (GL8) levobupivacaine combined with fentanyl in healthy patients undergoing elective cesarean section; secondary, to compare the duration and quality of analgesia and anesthesia

Read the detailed description

On arrival in the recovery room the ICG non-invasive blood pressure cuff will be placed on the left arm, two sensors will be placed above the clavicle on each side of the neck, and two sensors will bw placed on either side of the thorax at midaxillary line corresponding to the level of the xiphoid process. Using a computer- generated sequence of numbers, patients will be randomly allocated in one of the two groups: 6 mg (1.6 mL) levobupivacaine + 20 µg fentanyl (GL6 group) or 8 mg (2 mL) levobupivacaine + 20 µg fentanyl (GL8 group). Continuous spinal epidural anesthesia (CSE) will be performed with patient in sitting position: a 18-gauge Tuohy needle will be inserted into the L2-L3 interspace using the loss of resistance of saline technique to identify the epidural space; a 27-gauge Withacre spinal needle will be then placed through the Tuohy needle until the dura mater wwill be punctured and isobaric undiluted levobupivacaine plus 20 µg fentanyl was administered. Afterwards, an epidural catheter (Espocan, B.Braun, Melsungen, Germany) wwill be inserted 4 cm into the epidural space.

02

Conditions studied

  • Cesarean Section Complications
03

In context

Lead sponsor

University of Foggia is the lead sponsor of 35 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • pregnant undergoing elective Caesarean delivery at term of singleton pregnancy, with American Society of Anesthesiologists physical status of class I or II, without preeclampsia or diabetes,

Exclusion criteria

Exclusion Criteria:

  • Patient with a known allergy to amide local anesthetics and other drugs, with BMI≥40 kg/m2, cardiologic or systemic disease, in treatment with antihypertensive or anticoagulant
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
62 participants (actual)

Study arms

  • Sham comparator
    8 mg (2 mL) levobupivacaine

    8mg (2ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored

    Device: Impedance cardiography · Diagnostic Test: Sensory levels · Diagnostic Test: Motor block · Diagnostic Test: Sensory level

  • Active comparator
    6 mg (1.6 mL) levobupivacaine

    6mg (1.6ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored

    Device: Impedance cardiography · Diagnostic Test: Sensory levels · Diagnostic Test: Motor block · Diagnostic Test: Sensory level

Interventions

  • DeviceImpedance cardiography

    hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine

  • Diagnostic testSensory levels

    Sensory levels are checked using ice test cold

  • Diagnostic testMotor block

    motor block is measured by modified Bromage scale

  • Diagnostic testSensory level

    Sensory levels are checked using touch with alcohol puffs

06

What researchers measure

Primary outcomes

  1. hemodynamic continuous monitoring by impedance cardiography

    Impedance cardiography as a tool for hemodynamic monitoring during cesarean section

    Time frame: intraoperative time

Secondary outcomes

  1. onset of sensory block

    onset time of sensory block after intrathecal levobupivacaine

    Time frame: intraoperative time

  2. offset of sensory block

    offset time of sensory block after intrathecal levobupivacaine

    Time frame: intraoperative time

  3. onset of motor block

    onset time of motor block after intrathecal levobupivacaine

    Time frame: intraoperative time

  4. offset of motor block

    offset time of motor block after intrathecal levobupivacaine

    Time frame: intraoperative time

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • D'Ambrosio A, Cotoia A, Beck R, Salatto P, Zibar L, Cinnella G. Impedance cardiography as tool for continuous hemodynamic monitoring during cesarean section: randomized, prospective double blind study. BMC Anesthesiol. 2018 Mar 27;18(1):32. doi: 10.1186/s12871-018-0498-4. PubMed 29587655 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03170427
Lead sponsor
University of Foggia
Responsible party
Cotoia Antonella (researcher, University of Foggia) — Principal investigator
First posted
May 31, 2017
Start date
Jan 1, 2013
Primary completion
Jan 1, 2014
Completion
May 31, 2014
Last update
Oct 23, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion